CDKN3 and breast carcinoma: Among the multiple antitumor activities exerted by trastuzumab on HER2-overexpressing breast cancer cells, inhibition of cell proliferation is reported to occur primarily by modulation of the cyclin-dependent kinase inhibitor p27Kp1, via a complex network of signalling pathways, resulting in G1 arrest and growth inhibition [61].